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The consumption of omega-3 polyunsaturated fatty acids (n−3 PUFAs) has been reported
to reduce cardiac mortality following myocardial infarction as well as to decrease resting
heart rate (HR) and increase HR variability (HRV). However, it has not been established
whether n−3 PUFAs exhibit the same actions on HR and HRV in individuals known to be
either susceptible or resistant to ventricular ﬁbrillation (VF). Therefore, HR and HRV (high
frequency and total R–R interval variability) were evaluated before and 3months after n−3
PUFA treatment in dogs with healed myocardial infarction that were either susceptible
(VF+, n = 31) or resistant (VF−, n = 31) to ventricular tachyarrhythmias induced by a 2-min
coronary artery occlusion during the last minute of a submaximal exercise test. HR and
HRV were evaluated at rest, during submaximal exercise and in response to acute myocar-
dial ischemia at rest before and after either placebo (1 g/day, corn oil, VF+, n = 9;VF− n = 8)
or n−3 PUFA (docosahexaenoic acid+ eicosapentaenoic acid ethyl esters, 1–4 g/day, VF+,
n = 22; VF−, n = 23) treatment for 3months. The n−3 PUFA treatment elicited similar
increases in red blood cell membrane, right atrial, and left ventricular n−3 PUFA levels
in both the VF+ and VF− dogs. The n−3 PUFA treatment also provoked similar reduc-
tions in baseline HR and increases in baseline HRV in both groups that resulted in parallel
shifts in the response to either exercise or acute myocardial ischemia (that is, the change
in these variables induced by physiological challenges was not altered after n−3 PUFA
treatment). These data demonstrate that dietary n−3 PUFA decreased HR and increased
HRV to a similar extent in animals known to be prone to or resistant to malignant cardiac
tachyarrhythmias.
Keywords: parasympathetic nervous system, exercise, myocardial ischemia, fish oil, docosahexaenoic acid,
eicosapentaenoic acid
INTRODUCTION
There is strong association between abnormal cardiac autonomic
regulation and an increased risk for sudden cardiac death (Bill-
man, 2009). In particular, both patients and animals that exhibit
large reductions in cardiac parasympathetic activity coupled with
an enhanced sympathetic activation following myocardial infarc-
tion have an increased incidence of malignant ventricular tach-
yarrhythmias and sudden cardiac death (Billman, 2009). There-
fore, therapeutic interventions that improve cardiac balance could
protect against sudden death in high-risk patient populations.
A number of experimental and clinical studies report that
dietary omega-3 polyunsaturated fatty acids (n−3 PUFAs; Chris-
tensen et al., 1999; Christensen and Schmidt, 2007; Christensen,
2011) or the acute intravenous administration (Billman et al.,
1994) of these lipids can both lower resting heart rate (HR)
and increase resting HR variability (HRV), data consistent with
an enhanced baseline cardiac parasympathetic tone (Billman,
2009, 2011). It has been proposed that the cardiovascular bene-
ﬁts ascribed to dietary n−3 PUFAs could result, at least in part,
from these reductions in HR and the corresponding putative
improvements in cardiac autonomic balance (Christensen et al.,
1999; Christensen and Schmidt, 2007; Christensen, 2011) or
intrinsic rate (Laustiola et al., 1986; Kang and Leaf, 1994; Har-
ris et al., 2006; Verkerk et al., 2009; Billman and Harris, 2011).
Billman and Harris (2011) recently demonstrated that n−3 PUFA
supplements decrease baseline HR and increased baseline HRV in
animals with healed myocardial infarctions but did not alter the
response to physiological challenges (exercise or acute myocar-
dial ischemia). However, they did not determine whether the n−3
PUFA treatment elicited different actions in animals that were
known to be either resistant or susceptible to ventricular ﬁbril-
lation (VF). It is possible that those individuals with the greatest
impairment in cardiac autonomic regulation (and at the greatest
risk for adverse cardiac events) may exhibit larger changes in HRV
following n−3 PUFA treatment than patients with well-preserved
autonomic function.
It was, therefore, the purpose of the present study to evalu-
ate the effects of dietary n−3 PUFAs (1–4 g/day for 3months) on
the HR and the HRV responses to physiological stressors (exer-
cise or acute myocardial ischemia) in dogs with healed myocardial
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infarctions that had been identiﬁed as either being susceptible
(VF+) or resistant (VF−) to the induction of malignant ventric-
ular tachyarrhythmias. In particular, the hypothesis that dietary
n−3 PUFA supplements would produce different HR and HRV
responses to physiologic challenges in VF+ and VF− dogs was
tested.
MATERIALS AND METHODS
All the animal procedureswere approved by theOhio StateUniver-
sity Institutional Animal Care and Use Committee and conformed
to the Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH publication No.
85-23, revised 1996).
Archived data from 62 heartworm free mixed breed dogs (2-
to 3-year-old, male n = 20, female n = 42) weighing 19.9± 0.4 kg
(range 12.5–25.8 kg) that were part of an ongoing investigation
of the cardiovascular effects of dietary n−3 PUFA (Billman et al.,
2010, 2012; Billman and Harris, 2011) were used in the present
study. The sole selection criterion was an ECG signal of sufﬁ-
cient quality to determine HRV both at baseline and in response
to physiological challenges (i.e., exercise or acute myocardial
ischemia).
SURGICAL PREPARATION
The animals were anesthetized and instrumented to measure a
ventricular electrogram (from which HR and HRV were subse-
quently determined) and left circumﬂex coronary artery blood
ﬂow as previously described (Billman et al., 1982; Schwartz et al.,
1984; Billman, 2006). A hydraulic vascular occluder (Model OC3,
In vivo Metric, Healdsburg, CA, USA) was placed around the left
circumﬂex coronary artery and used to induce acute myocardial
ischemia for the coronary occlusion experiments described below
(see the HRV protocols). The left anterior descending coronary
artery was also isolated during the instrumentation surgery and
a two-stage occlusion of this artery was then performed approxi-
mately one-third the distance from its origin in order to produce
an anterior wall myocardial infarction [∼16% of left ventricular
mass (Billman, 2006]. This vessel was partially occluded for 20min
and then tied off. The dogs were given analgesic, antibiotic, and
anti-arrhythmic therapy to alleviate post-operative pain, to pre-
vent post-operative infection, and to reduce acute arrhythmias
associated with the myocardial infarction as has been previously
described (Billman et al., 1982; Schwartz et al., 1984; Billman,
2006).
EXERCISE PLUS ISCHEMIA TEST
The studies began 3–4weeks after the production of the myocar-
dial infarction. The susceptibility to VF was tested as previously
described (Billman et al., 1982; Schwartz et al., 1984; Billman,
2006). Brieﬂy, the animals ran on a motor-driven treadmill while
workload progressively increased until a HR of 70% of maxi-
mum (approximately 210 beats/min) had been achieved. During
the last minute (on average during the 18th minute) of exercise,
the left circumﬂex coronary artery was occluded, the treadmill
stopped, and the occlusion maintained for an additional minute
(total occlusion time= 2min). The exercise plus ischemia test reli-
ably induced ventricular ﬂutter that rapidly deteriorated into VF.
Therefore, large deﬁbrillation electrodes (Adult Stat-padz, Zoll
Medical, Burlington, MA, USA) were placed across the animal’s
chest so that electrical deﬁbrillation (Zoll M series deﬁbrillator)
could be achieved with a minimal delay but only after the animal
was unconscious (10–20 s after the onset of VF). The occlusion
was immediately released if VF occurred. In the present study, 31
dogs developed VF (susceptible, VF+) while 31 did not (resistant,
VF−).
HEART RATE VARIABILITY PROTOCOLS
Heart rate variabilitywas calculated using aDelta-Biometrics vagal
tone monitor triggering off the electrocardiogram R–R interval
(Urbana-Champaign, IL, USA). This device employs the time-
series signal processing techniques as developed by Porges to esti-
mate the amplitude of respiratory sinus arrhythmia [the high fre-
quency,HF component of R–R interval variability (Porges, 1986)].
Details of this analysis have been described previously (Billman
and Hoskins, 1989; Billman and Dujardin, 1990; Houle and Bill-
man, 1999). Data were averaged over 30 s intervals either during
exercise or the coronary occlusion. The following indices of HRV
were determined: Vagal Tone Index, the HF (0.24–1.04Hz) com-
ponent of R–R interval variability, and the SD of the R–R intervals
(a marker of total variability) for the same 30 s time periods.
First, over the period of 3–5 days, the dogs learned to run on a
motor-driven treadmill. The cardiac response to submaximal (i.e.,
60–70% of maximal HR) exercise was then evaluated as follows:
exercise lasted a total of 18min with workload increasing every 3-
min. The protocol began with a 3-min “warm-up” period, during
which the dogs ran at 4.8 kph at 0% grade. The speed was then
increased to 6.4 kph, and the grade increased every 3-min (0, 4,
8, 12, and 16%). The submaximal exercise test was repeated three
times (one/day). On a subsequent day, with the dogs lying quietly
unrestrained on a table, a 2-min left circumﬂex coronary occlusion
was made. Left circumﬂex blood ﬂow, HR, and HRV were mon-
itored continuously throughout the exercise or occlusion studies.
The submaximal exercise and the coronary occlusion at rest stud-
ies were performed both before and after 3months of treatment
with either placebo (1 g/day corn oil) or daily n−3 PUFA capsules
(1–4 g/day).
DIETARY OMEGA-3 POLYUNSATURATED FATTY ACID PROTOCOL
The dogs were placed on a diet that did not contain any n−3
PUFAs (Harlan Teklad, Harlan Laboratories, Inc., Indianapolis,
IN, USA) beginning 1week prior to the instrumentation surgery
and were maintained on this diet until the end of the study
(∼4months). After the pre-treatment data collection (3–4weeks
after the surgery), the dogs were then randomly assigned to the
following groups: placebo (n = 17: S, n = 9; R, n = 8); n−3 PUFA
(1–4 g/day, n = 45: S, n = 22; R, n = 23). The dogs were given sup-
plements similar to those used in the GISSI-Prevenzione study
(Di Stasi et al., 2004). The n−3 PUFA group received 465mg ethyl
eicosapentaenoate, EPA+ ethyl docosahexaenoate, DHA, 375mg
per 1 g capsule (Lovaza®, GlaxoSmithKline, Research Triangle
Park, NC, USA). The placebo was corn oil (1 g, 58% linoleic
acid+ 28% oleic acid). The capsules were given per os prior to
the daily feeding (between 8:00 and 10:00 a.m. each day, 7 days per
week for 3months).
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RED BLOOD CELL AND CARDIAC TISSUE FATTY ACID ANALYSIS
Fasting blood samples (5ml) were drawn into EDTA tubes from
a cephalic vein between 8:00 and 9:00 a.m. 1 day prior to the ini-
tiation of the treatment (placebo or n−3 PUFA) and when tissue
was harvested at the end of the study (∼14weeks after the treat-
ment began). Right atrial and left ventricular tissue were obtained
when the hearts were harvested; the tissue and red blood cells
(RBC) were ﬂash frozen in liquid nitrogen; and stored at −80˚C
for future analysis.
Red blood cell and phospholipids from cardiac tissue were
analyzed for fatty acid composition using previously described
techniques (Bligh andDyer, 1959;Morrison and Smith, 1964). The
samples were analyzed by gas chromatography using a GC2010-
FID (ShimadzuCorporation,Columbia,MD,USA) equippedwith
a 100-mm capillary column (SP-2560, Supelco, Bellefonte, PA,
USA). Fatty acids of interest were identiﬁed by comparison with
known standards and expressed as a percent of total fatty acids. The
coefﬁcient of variation for the RBC EPA+DHA assays was<5%.
DATA ANALYSIS
All data are reported as mean± SEM. The data were digitized
(1 kHz) and recorded using a Biopac MP-100 data acquisition sys-
tem (Biopac Systems, Inc., Goleta, CA, USA). The HR and HRV
data were averaged over 30 s intervals either during exercise or the
coronary occlusion. ECG variables were averaged over the last ﬁve
beats before and 60 s after the onset of the coronary occlusion.
QT interval was corrected for changes in HR using Van de Water’s
correction formula [QTc =QT− 87(60/HR− 1)] (Van de Water
et al., 1989).
The data were compared using ANOVA for repeated mea-
sures (NCSS statistical software, Kaysville,UT,USA). For example,
the effects of n−3 PUFAs on the HR and HRV response to
either submaximal exercise or the coronary artery occlusion at
rest for the resistant or susceptible dogs were analyzed using a
three factor ANOVA [pre–post (two levels)× dose (placebo vs.
n−3 PUFA)× time (exercise seven levels or occlusion six levels)
with repeated measures on two factors (pre–post and time)]. The
effect of n−3 PUFA on ECG variables before and 60 s after coro-
nary occlusion for the resistant or susceptible dogs were evaluated
using a three factor [pre–post (two levels), dose (two levels), and
occlusion time (two levels, before and 60 s after occlusion onset
points)] ANOVA with repeated measure on two (pre–post and
occlusion time) factors. Homogeneity of covariance (sphericity
assumption, equal correlates between the treatments) was tested
using Mauchly’s test and, if appropriate, adjusted using Huynh–
Feldt correction. RBC and cardiac tissue lipid compositions were
compared using a three factor ANOVA [group (VF+ vs. VF−),
dose (placebo vs. n−3 PUFA), pre–post] with repeated mea-
sures on one factor (pre–post) or a two factor ANOVA [group
(susceptible vs. resistant), dose (placebo vs. n−3 PUFA], respec-
tively. If the F value exceeded a critical value (P < 0.05), post hoc
comparisons of the data were then made using Tukey–Kramer
Multiple-Comparison Test.
RESULTS
EFFECT OF n−3 PUFA ON RED BLOOD CELL AND CARDIAC TISSUE
FATTY ACID CONTENT
In agreement with previous studies (Billman et al., 2010; Bill-
man, 2011), n−3 PUFA supplements elicited signiﬁcant (dose
effect, pre–post, and dose× pre–post interaction, all P < 10−6)
increases in RBC membrane EPA, DHA, and the omega-3
index (EPA+DHA) as compared to the placebo treated ani-
mals (Table 1). Similar increases in EPA, DHA, and the omega-3
index were noted for both the susceptible and the resistant dogs
(i.e., there were no signiﬁcant group, group× dose interactions,
or group× pre–post interactions). Thus, n−3 PUFA treatment
increased RBC n−3 PUFA content to a similar extent in both the
VF+ and VF− dogs while lipid composition did not change dur-
ing the 3-month study period in the placebo treated dogs in either
group. In a similar manner, right atrial and left ventricular n−3
PUFA content was signiﬁcantly higher (P < 10−6) in n−3 PUFA
compared to the placebo treated animals (Table 2). Once again
these increases were similar in both the VF+ and VF− groups
(i.e., there were no group or group× dose interactions for the
either the LV or for the RA tissue).
EFFECT OF n−3 PUFA ON BASELINE HEART RATE AND HEART RATE
VARIABILITY
The effect of n−3 PUFA or placebo on baseline (i.e., before a phys-
iological challenge) HR and HRV are listed in Table 3. The n−3
PUFA treatment elicited signiﬁcant reductions inHR (P < 0.0002)
Table 1 | Red blood cell omega-3 polyunsaturated fatty acid content.
EPA DHA Omega-3 index
Pre Post Pre Post Pre Post
PLACEBO
VF− (n =4) 0.17±0.01 0.15±0.03 0.30±0.05 0.13±0.02 0.47±0.04 0.28±0.05
VF+ (n =7) 0.14±0.01 0.20±0.02 0.20±0.01 0.24±0.05 0.34±0.02 0.41±0.04
n−3 PUFA
VF− (n =23) 0.18±0.02 3.28±0.29*+ 0.23±0.02 2.63±0.16*+ 0.40±0.04 5.94±0.42*+
VF+ (n =22) 0.20±0.01 2.79±0.33*+ 0.27±0.05 2.52±0.19*+ 0.52±0.07 5.31±0.45*+
All values are expressed of % of the total lipid content. EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; omega-3 index, EPA+DHA, *P<0.01 pre vs. post,
+P<0.01 placebo vs. n−3 PUFA (omega-3 polyunsaturated fatty acids). There were no signiﬁcant differences between VF− (resistant to ventricular ﬁbrillation) and
VF+ (susceptible to ventricular ﬁbrillation) for either the placebo or n−3 PUFA treated animals.
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Table 2 | Cardiac tissue omega-3 polyunsaturated fatty acid content.
EPA DHA Omega-3 index
RIGHTATRIUM
Placebo
VF− 0.11±0.08 0.16±0.10 0.27±0.18 (n =3)
VF+ 0.36±0.12 0.58±0.17 0.91±0.25 (n =6)
n−3 PUFA
VF− 2.04±0.31* 2.89±0.33* 4.92±0.59* (n =23)
VF+ 1.62±0.25* 2.80±0.37* 4.41±0.61* (n =22)
LEFTVENTRICLE
Placebo
VF− 0.12±0.06 0.19±0.06 0.31±0.11 (n =3)
VF+ 0.34±0.05 0.45±0.10 0.80±0.13 (n =6)
n−3 PUFA
VF− 2.98±0.30* 3.00±0.17* 5.98±0.43* (n =23)
VF+ 2.27±0.28* 2.80±0.20* 4.41±0.43* (n =21)
All values are expressed of % of the total lipid content. EPA, eicosapentaenoic
acid; DHA, docosahexaenoic acid; omega-3 index, EPA+DHA, *P<0.01 placebo
vs. n−3 PUFA (omega-3 polyunsaturated fatty acids). There were no signiﬁcant
differences betweenVF− (resistant to ventricular ﬁbrillation) andVF+ (susceptible
to ventricular ﬁbrillation) for either the placebo or n−3 PUFA treated animals.
thatwere accompaniedby a corresponding increase in theHFcom-
ponent (HF, 0.24–1.04Hz) of R–R interval variability (P < 0.002)
in both the VF− and VF+ animals. However, total beat-to-beat
variability as measured by the SD of R–R variability was not
altered by n−3 PUFA treatment. There were no differences noted
between the VF+ and VF− dogs (no signiﬁcant group effect or
group× pre–post interactions). In contrast, placebo treatment did
not alter either baseline HR, HF, or SD in either the VF− or in
the VF+ groups (Table 3). Thus, n−3 PUFA treatment provoked
changes in resting HR and HRV in both VF− and VF+ dogs that
were consistent with either an enhanced cardiac vagal regulation
(Task Force of the European Society of Cardiology and the North
American Society of Pacing and Electrophysiology, 1996; Berntson
et al., 1997; Billman, 2009, 2011) or a change in baseline intrinsic
rate (Verkerk et al., 2009; Billman and Harris, 2011).
EFFECT OF n−3 PUFA ON THE ECG VARIABLES, HEART RATE, AND
HEART RATE VARIABILITY RESPONSE TO ACUTE MYOCARDIAL
ISCHEMIA
The effects of the placebo and the n−3 PUFA treatment on ECG
parameters at baseline and in response to coronary artery occlu-
sion for theVF+ andVF− dogs are listed in Table 4. The coronary
occlusion provoked signiﬁcant increases in HR (both VF+ and
VF−, P < 10−6) and the descending portion of the T wave (VF+
only, P < 0.00003), a marker of the dispersion of repolarization
(Yan and Antzelevitch, 1998; Opthof et al., 2007) while elicit-
ing decreases in PR interval (VF+, P < 0.0001; VF−, P < 0.002).
No other ECG variable was affected by the ischemia. The n−3
PUFA treatment (but not placebo) elicited signiﬁcant reductions
in HR (VF+, P < 0.04; VF−, P < 0.04) and increases in PR inter-
val (VF+,P < 0.02;VF−,P < 0.03), changes that weremaintained
during the coronary occlusion. Interestingly, pre-occlusion QTc
interval increased in both the placebo and n−3 PUFA treatment
Table 3 | Effect of dietary omega-3 polyunsaturated fatty acids on
heart rate and heart rate variability.
Pre-treatment Post-treatment
HEART RATE (BEATS/MIN)
VF+
Placebo (n =9) 122.4±4.7 121.6±4.20
n−3 PUFA (n =22) 123.3±4.5 112.6±4.2*
VF−
Placebo (n =8) 123.3±5.2 127.0±6.0
n−3 PUFA (n =23) 122.3±4.1 106.9±3.8*
HIGH FREQUENCY (0.24–1.04Hz)VARIABILITY (ln ms2)
VF+
Placebo 6.7±0.3 6.3±0.5
n−3 PUFA 7.0±0.3 7.5±0.2*
VF−
Placebo 7.0±0.3 6.7±0.4
n−3 PUFA 6.7±0.3 7.7±0.3*
R–R INTERVAL SD (ms)
VF+
Placebo 60.2±6.9 67.8±10.2
n−3 PUFA 59.0±6.6 69.8±5.8
VF−
Placebo 69.6±8.2 68.8±9.4
n−3 PUFA 65.9±10.3 74.8±6.3
*P<0.01 Pre-treatment vs. Post-treatment; n−3 PUFA, omega-3 polyunsaturated
fatty acids;VF+, susceptible to ventricular ﬁbrillation;VF−, resistant to ventricular
ﬁbrillation.
(VF+,P < 0.02;VF−,P < 0.0001) at the end of the 3-month treat-
ment period as compared to values obtained before the treatment
began.
The effects of placebo and the n−3 PUFA treatment on the HR
and HRV (HF only) response to the acute myocardial ischemia
are displayed for VF+ and VF− dogs in Figures 1 and 2, respec-
tively. In agreement with previous studies (Collins and Billman,
1989; Halliwill et al., 1998; Houle and Billman, 1999; Billman,
2006; Billman and Kukielka, 2006), the coronary occlusion sig-
niﬁcantly increased HR (occlusion time effect, P < 10−6) and
decreased HRV (both HF and SD, occlusion time effect,P < 10−6)
in the placebo and in the n−3 PUFA treated animals. HR was
signiﬁcantly lower (pre–post, VF− P < 0.0004; VF+ P < 0.02),
and both HF (pre–post, VF− P < 0.0001; VF+ P < 0.03) and
SD (data not shown pre–post, VF− P < 0.009; VF+ P < 0.05)
were higher during the coronary occlusion after n−3 PUFA
treatment as compared to values obtained prior to the treat-
ment. However, the absolute change in these variables induced
by myocardial ischemia (VF−:ΔHR pre-treatment 23.5± 4.3 vs.
post-treatment 19.7± 4.6 beats/min,ΔHF pre −3.5± 0.4 vs. post
−2.5± 0.5 lnms2;ΔSD pre −39.3± 10.5 vs. post −25.9± 6.5ms;
VF+:ΔHR pre 41.2± 5.8 vs. post 35.5± 6.8 beats/min,ΔHF pre
−4.4± 0.5 vs. post −3.6± 0.6 lnms2; ΔSD pre −39.0± 7.9 vs.
post −32.8± 7.0ms) was not altered by the n−3 PUFA treat-
ment (i.e., there were no signiﬁcant pre–post× time interactions
for either group). Thus, n−3 PUFA treatment elicited a similar
downward shift in resting HR and an upward shift in the resting
Frontiers in Physiology | Cardiac Electrophysiology March 2012 | Volume 3 | Article 71 | 4
Billman Dietary n−3 PUFAs increase HRV
Table 4 | Effect of dietary omega-3 fatty acids on ECG parameters at
baseline and during coronary artery occlusion.
Pre-treatment Post-treatment
Control Occlusion Control Occlusion
HEART RATE (BEATS/MIN)
VF+
Placebo 125.6±7.1 172.9±13.6* 124.6±8.4 168.6±16.4*
n−3 PUFA 126.7±5.1 163.9±7.3* 113.9±4.3# 147.3±6.9*#
VF−
Placebo 122.8±7.2 148.1±12.9* 125.4±9.3 144.7±10.3*
n−3 PUFA 128.6±4.7 146.7±6.0* 116.2±4.1# 139.4±5.9*
PR INTERVAL (ms)
VF+
Placebo 91.2±4.9 77.6±6.2* 98.8±5.5 83.8±2.6*
n−3 PUFA 95.3±3.5 87.1±3.5* 104.9±3.4# 96.8±3.5*#
VF−
Placebo 99.6±3.7 83.6±4.2* 102.3±4.1 99.4±5.0*
n−3 PUFA 98.7±3.4 88.6±3.7* 103.4±3.2 95.4±4.2*
QRS DURATION (ms)
VF+
Placebo 77.2±4.3 78.2±4.7 79.6±3.9 79.1±2.1
n−3 PUFA 82.8±1.6 79.0±2.1 82.0±1.1 80.9±1.6
VF−
Placebo 83.4±2.9 81.1±2.9 88.3±1.6 86.3±2.0
n−3 PUFA 80.0±1.9 79.4±2.0 82.5±1.5 82.1±1.5
QTc INTERVAL (ms)
VF+
Placebo 245.6±5.0 248.0±5.2 263.8±5.4# 250.7±5.4
n−3 PUFA 256.2±3.6 257.9±5.8 272.4±3.3# 261.9±3.6#
VF−
Placebo 251.0±7.5 255.1±5.4 278.0±3.7# 268.3±5.4#
n−3 PUFA 252.4±3.1 248.6±3.2 270.2±3.9# 268.3±4.7#
TPEAK–TEND (CORRECTED; ms)
VF+
Placebo 89.1±6.2 97.7±6.3* 87.11±3.5 110.3±7.3*
n−3 PUFA 87.7±3.2 103.6±3.7* 89.5±2.9 105.4±4.5*
VF−
Placebo 86.9±4.5 92.7±5.1 90.7±4.8 91.3±7.1
n−3 PUFA 88.6±3.1 85.6±4.6 89.0±4.5 92.4±4.6
*P<0.01 control vs. coronary artery occlusion (60 s after occlusion onset);
#P<0.01 Pre-treatment vs. Post-treatment; n−3 PUFA, omega-3 polyunsaturated
fatty acids.
Heart rate correction: QTc=QT−87(60/HR−1); Tpeak–Tend (corrected)=Tpeak–
Tend −87(60/HR−1) (Van de Water et al., 1989); VF+, susceptible to ventricular
ﬁbrillation, VF−, resistant to ventricular ﬁbrillation.
HRV in both VF+ and VF− animals but did not alter the magni-
tude of the change in these variables that was induced by the coro-
nary artery occlusion (i.e., the response to the coronary occlusion
per se was not affected by the treatment) in either group.
In contrast, the placebo treatment did not alter the HR, HF, or
SD (i.e., there were no signiﬁcant pre–post effects) response to the
coronary occlusion in the VF− dogs. In the VF+ dogs, the coro-
nary occlusion elicited larger increases in HR (pre–post, P < 0.01)
FIGURE 1 | Effect of omega-3 polyunsaturated fatty acids (n−3 PUFAs)
on the heart rate and heart rate variability response to acute
myocardial ischemia (2min left circumflex coronary artery occlusion)
in dogs susceptible to ventricular fibrillation. Dietary n−3 PUFA, but not
the placebo, produced a signiﬁcant downward shift of the heart rate (HR)
response that was accompanied by an upward shift in the high frequency
(HF) component of the R–R interval variability (vagal tone index
0.24–1.04Hz; i.e., signiﬁcant pre–post-treatment effect: HR, P <0.02; HF,
P <0.03). Despite the shifts in the curves, the absolute change in these
variables induced by the coronary artery occlusion was not altered before
or after the treatment (i.e., there were no signiﬁcant
pre–post-treatment× coronary occlusion interactions: HR P =0.57; HF,
P =0.47). Placebo (n =9) or n−3 PUFA (1–4 g/day, n =22), pre=before
treatment began, post= after 3months of treatment.
at the end of the 3-month study period, but neither HF nor SD (no
signiﬁcant pre–post effect) was altered by the placebo treatment.
As was noted following n−3 PUFA treatment, the absolute change
in these variables induced by myocardial ischemia was also similar
(i.e., there were no signiﬁcant pre–post× occlusion interactions)
in bothVF− andVF+ animals before and at the end of the placebo
treatment.
EFFECT OF n−3 PUFA ON THE HEART RATE AND HEART RATE
VARIABILITY RESPONSE TO SUBMAXIMAL EXERCISE
The HR and HRV response to submaximal exercise before and
after 3months of placebo or n−3 PUFA treatment are displayed
inFigure 3 (VF+) andFigure 4 (VF−).As onewouldpredict, exer-
cise provoked large increases inHR (exercise level effect,P < 10−6)
that were accompanied by large reductions in HRV (exercise level
effect, P < 10−6) in all four groups. HR was signiﬁcantly lower
(pre–post effect: VF−, P < 0.05; VF+, P < 0.04), and both HF
(pre–post:VF−,P < 0.02;VF+,P < 0.02) and SD (data not shown
pre–post: VF−, P < 0.0004; VF+, P < 0.005) were higher during
exercise aftern−3PUFA treatment as compared to values obtained
prior to the treatment. In contrast,HR,HF,andSDwerenot altered
(no signiﬁcant pre–post effects) by the placebo treatment. The
change in HR (VF−, pre-treatment 62.4± 6.7 vs. post-treatment
66.6± 5.5; VF+, pre 65.8± 5.3 vs. post 59.8± 6.3 beats/min), HF
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FIGURE 2 | Effect of omega-3 polyunsaturated fatty acids (n−3 PUFAs)
on the heart rate and heart rate variability response to acute
myocardial ischemia (2min left circumflex coronary artery occlusion)
in dogs resistant to ventricular fibrillation. Dietary n−3 PUFA, but not
the placebo, produced a signiﬁcant downward shift of the heart rate (HR)
response that was accompanied by an upward shift in the high frequency
(HF) component of the R–R interval variability (vagal tone index
0.24–1.04Hz; i.e., signiﬁcant pre–post-treatment effect: HR, P <0.004; HF,
P <0.001). Despite the shifts in the curves, the absolute change in these
variables induced by the coronary artery occlusion was not altered before
or after the treatment (i.e., there were no signiﬁcant
pre–post-treatment× coronary occlusion interactions: HR, 0.27; HF,
P =0.07). Placebo (n =8) or n−3 PUFA (1–4 g/day, n =23), pre=before
treatment began, post= after 3months of treatment.
(VF−, pre −4.9± 0.3 vs. post −5.0± 0.2; VF+, pre −6.2± 0.5 vs.
post −6.3± 0.5 lnms2), and SD (VF−, pre −44.5± 4.2 vs. post
60.3± 9.3; VF+, −36.5± 4.7 vs. post −47.7± 6.3ms) provoked
by exercise were not affected by the n−3 PUFA treatment (i.e.,
there were no signiﬁcant pre–post× exercise level interactions).
Thus, n−3 PUFA produced a similar shift in the pre-exercise val-
ues of HR,HF, and SD in bothVF+ andVF− animals and, further,
the magnitude of the change in these variables that was induced
by exercise was not altered by n−3 PUFA for either group. In
other words, the response to exercise per se was not affected by the
treatment.
DISCUSSION
The present study investigated the effects of dietary n−3 PUFA (1–
4 g/day for 3months) onHRandHRV(both at baseline andduring
physiological stress – exercise or acute myocardial ischemia) in
dogs with healed myocardial infarction that were known to be
either susceptible or resistant to VF. The major ﬁndings of the
study are as follows: ﬁrst, and in agreement with previous stud-
ies (Harris et al., 2004, 2006; Billman et al., 2010; Billman and
Harris, 2011), the n−3 PUFA treatment elicited increases in both
RBC and cardiac (right atrial and left ventricular) tissue DHA and
EPA content. Second, consistent with previous observations (Bill-
man and Harris, 2011) n−3 PUFA, but not placebo, treatment
FIGURE 3 | Effect of omega-3 polyunsaturated fatty acids (n−3 PUFAs)
on the heart rate and heart rate variability response to submaximal
exercise in dogs susceptible to ventricular fibrillation. Dietary n−3
PUFA, but not the placebo, produced a signiﬁcant downward shift of the
heart rate (HR) response curve that was accompanied by an upward shift in
the high frequency (HF) component of the R–R interval variability (vagal
tone index 0.24–1.04Hz; i.e., signiﬁcant pre–post effect: HR, P <0.04; HF,
P <0.02). Despite the shifts in the curves, the absolute change in these
variables induced by the exercise was not altered before or after the
treatment (i.e., there were no signiﬁcant pre–post-treatment×exercise
interactions: HR, P =0.68; HF, P =0.45). The data were averaged over the
last 30 s of given exercise level. Exercise levels are as follows: 1=0 kph and
0% grade; 2=4.8 kph and 0% grade; 3=6.4 kph and 0% grade; 4=6.4 kph
and 4% grade; 5=6.4 kph and 8% grade; 6=6.4 kph and 12% grade;
7=6.4 kph and 16% grade. Pre=before placebo (n =9) or n−3 PUFA
(1–4 g/day, n =22) treatment began, post= after 3months of treatment.
elicited reductions in baseline HR, increases in HRV and increases
in PR interval. No other ECG parameter was affected by the n−3
PUFA treatment. Thus, although the acute application of n−3
PUFAs have been shown to decrease action potential duration in
isolated cardiomyocytes (Verkerk et al., 2006; den Ruijter et al.,
2008, 2010), long-term n−3 PUFA treatment did not alter global
indices of ventricular repolarization in the present study. Interest-
ingly, QT interval corrected for a HR increased at the end of the
3-month treatment period in both the placebo and the n−3 PUFA
treated groups,data consistentwith a time-dependent electrophys-
iological remodeling that results as a consequence of myocardial
infarction. Third, although the peak values obtained during the
stimulus were lower after n−3 PUFA treatment as compared to
values reached before the treatment began, the absolute magni-
tude of the change in HR and HRV provoked by either exercise
or acute myocardial ischemia was not altered by n−3 PUFA treat-
ment and was similar to that recorded for the placebo groups. In
other words, the n−3 PUFA treatment produced parallel shifts
in the response to either exercise or the coronary occlusion due
to changes in baseline (pre-challenge) HR and HRV. Fourth, the
changes in both the baselineHRandHRVand the changes induced
in these variables by a physiological challenge were nearly identical
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FIGURE 4 | Effect of omega-3 polyunsaturated fatty acids (n−3 PUFAs)
on the heart rate and heart rate variability response to submaximal
exercise in dogs resistant to ventricular fibrillation. Dietary n−3 PUFA,
but not the placebo, produced a signiﬁcant downward shift of the heart rate
(HR) response curve that was accompanied by an upward shift in the high
frequency (HF) component of the R–R interval variability (vagal tone index
0.24–1.04Hz; i.e., signiﬁcant pre–post effect: HR, P <0.05; HF, P <0.02).
Despite the shifts in the curves, the absolute change in these variables
induced by the exercise was not altered before or after the treatment (i.e.,
there were no signiﬁcant pre–post-treatment×exercise interactions: HR,
P =0.67; HF, P =0.88). The data were averaged over the last 30 s of given
exercise level. Exercise levels are as follows: 1=0 kph and 0% grade;
2=4.8 kph and 0% grade; 3=6.4 kph and 0% grade; 4=6.4 kph and 4%
grade; 5=6.4 kph and 8% grade; 6=6.4 kph and 12% grade; 7=6.4 kph
and 16% grade. Pre=before placebo (n =8) or n−3 PUFA (1–4 g/day,
n =23) treatment began, post= after 3months of treatment.
in the susceptible and resistant dogs. These data suggest that
despite signiﬁcantly different initial responses (VF+ animals had a
higher HR and lower HRV during exercise or myocardial ischemia
as compared to the VF− dogs), n−3 PUFA treatment produced
similar changes in HR and HRV in dogs that either exhibited VF
or had no arrhythmias induced by myocardial ischemia.
EFFECT OF n−3 PUFA ON RESTING HEART RATE AND HEART RATE
VARIABILITY
In agreement with the present study, a number of clinical (Chris-
tensen et al., 1999; Christensen and Schmidt, 2007; Carney et al.,
2010;Christensen,2011) and experimental studies (Laustiola et al.,
1986;Kang andLeaf,1994;Billman et al., 2010;Billman andHarris,
2011;Mayyas et al., 2011) report that n−3 PUFA ingestion or acute
intravenous administration (Billman et al., 1994) lower HR and
increase HRV, suggestive of an increase in cardiac parasympathetic
regulation. However, there are also studies in which n−3 PUFA
failed to alter either HRV or other measures of autonomic func-
tion (Russo et al., 1995; Geelen et al., 2003; Hamaad et al., 2006),
such as baroreceptor sensitivity (Geelen et al., 2003). Furthermore,
even in the studies that reported a positive action of n−3 PUFAs
on HR or HRV, the effect was often quite small (Mozaffarian et al.,
2005, 2006, 2008). For example, a meta-analysis of 30 trials found
that ﬁsh oil supplements (approximately 3.5 g/day of EPA+DHA)
reduced baseline HR by 2.5 beats/min (Mozaffarian et al., 2005),
while Mozaffarian et al. (2008) reported that individuals with
the highest ﬁsh consumption (≥5meals per weak) only exhib-
ited 1.5ms greater HRV compared to those with the lowest ﬁsh
consumption. Although this difference was statistically signiﬁcant,
such a small change in resting HRV is not likely to be physiolog-
ically relevant. Indeed, these investigators calculated that only a
1.1% reduction in the relative risk for sudden cardiac death could
be associated with this very modest increase in HRV (Mozaffarian
et al., 2008). However, these small changes could have important
consequences if they are maintained during a physiological stres-
sor such as exercise or acute myocardial ischemia. Reductions in
HR would reduce metabolic demand placed on the heart partic-
ularly when oxygen supply is compromised by coronary artery
lesions/obstructions. The resulting better match between oxygen
supply and oxygen demand would, indirectly, decrease the risk
for adverse cardiac events associated with myocardial ischemia.
In fact, individuals with the lowest resting HRs also exhibited the
lowest long-term (>20 years) mortality rate (Jouven et al., 2009).
Furthermore, the beneﬁcial effects of beta-adrenergic receptor
antagonists, the most effective anti-arrhythmic medication, have
been attributed to the negative chronotropic actions of these drugs
(Held and Yusuf, 1993). However, it has been recently reported
that n−3 PUFA treatment not only failed to prevent malignant
arrhythmias in VF+ animals, but actually increased ventricular
tachyarrhythmias in VF− dogs (Billman et al., 2012). Thus, n−3
PUFA mediated reductions in HR were not sufﬁcient to protect
against malignant arrhythmias.
EFFECT OF n−3 PUFA ON HEART RATE AND HEART VARIABILITY
RESPONSE TO MYOCARDIAL ISCHEMIA
As expected from previous studies (Collins and Billman, 1989;
Halliwill et al., 1998; Houle and Billman, 1999; Billman, 2006; Bill-
man and Kukielka, 2006), the coronary artery occlusion elicited a
robust HR increase that was accompanied by a rapid withdrawal
in parasympathetic regulation as indicated by the decline in both
total R–R interval variability (SD) and the HF component of R–R
interval variability. However, despite alterations in pre-occlusion
HR and HRV, the cardiac response to coronary artery occlusion
was not altered by the n−3 PUFA treatment in either the VF+
or the VF− groups. The n−3 PUFA treatment produced parallel
shifts in the coronary occlusion response curves (due to changes in
the pre-occlusion HR and HRV) but the magnitude of the change
in these variables was not altered by the n−3 PUFA treatment. As
the robust autonomic response to the coronary occlusion was not
altered, the changes in pre-ischemic HR and HRV induced by the
n−3PUFAmay be insufﬁcient to preventmalignant changes in the
cardiac rhythm. In fact, as was previously noted, long-term n−3
PUFA treatment failed to prevent ischemically induced arrhyth-
mias in the same canine model of sudden cardiac as used in the
present study (Billman et al., 2012). These results are analogous to
those obtained following treatment with low doses of the choliner-
gic antagonist atropine (Kottmeier andGravenstein, 1968; Casadei
et al., 1993; De Ferrari et al., 1993; Hull et al., 1995; Halliwill et al.,
1998). Using the same canine model of myocardial infarction,
low dose atropine decreased baseline HR and increased HRV but,
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as in the present study, did not alter the response to myocardial
ischemia (Halliwill et al., 1998). This intervention also failed to
prevent the induction ofVF (Hull et al., 1995;Halliwill et al., 1998).
In marked contrast, however, exercise training not only improved
resting HR and HRV but also dramatically reduced the response to
coronary occlusion and completely suppressed the formation of
malignant ventricular tachyarrhythmias (Billman and Kukielka,
2006). When considered together these results strongly suggest
that, in order to be effective, an intervention must enhance cardiac
parasympathetic regulation during myocardial ischemia; resting
changes alone may be insufﬁcient to protect against malignant
arrhythmias.
EFFECT OF n−3 PUFA ON HEART RATE AND HEART VARIABILITY
RESPONSE TO EXERCISE
In agreement with previous human (O’Keefe et al., 2006; Ninio
et al., 2008; Peoples et al., 2008; Buckley et al., 2009) and animal
studies (Billman and Harris, 2011), dietary n−3 PUFA treat-
ment also elicited similar parallel shifts in HR and HRV during
exercise but did not alter the response in placebo treated dogs.
Furthermore, n−3 PUFA provoked nearly identical changes in
HR and HRV in both the VF+ and VF− animals. In contrast, an
endurance exercise training program(10weeks treadmill running)
both improved resting HR and HRV and attenuated the cardiac
response to submaximal exercise in the same canine model as was
used in the present study (Billman and Kukielka, 2006, 2007).
Unlike n−3 PUFA treatment, exercise training also elicited much
larger reductions in HR and increases in HRV in VF+ as com-
pared to VF− animals (Billman and Kukielka, 2006, 2007). Thus,
exercise training, in marked contrast to n−3 PUFA treatment,
can elicit larger changes (improvements) in HRV in the animals
with more pronounced impairments in cardiac autonomic func-
tion than in the dogs with more modest changes in autonomic
regulation following myocardial infarction.
LIMITATIONS OF THE STUDY
In the present study cardiac vagal nerve activity was not directly
recorded. Cardiac parasympathetic regulation was only indirectly
evaluated using non-invasivemarkers of HRV.Although a number
of studies provide strong evidence that beat-to-beat ﬂuctuation in
HR reﬂect corresponding changes in cardiac parasympathetic reg-
ulation (Task Force of the European Society of Cardiology and the
North American Society of Pacing and Electrophysiology, 1996;
Berntson et al., 1997; Parati et al., 2006; Billman, 2009, 2011),
an accurate assessment of nerve activity can only be obtained
from direct nerve recordings. As such, HRV data should always
be interpreted with care.
Second, previous studies demonstrate that ventricular func-
tion is not altered by myocardial infarction in the canine model
used in the present study (Billman et al., 1985, 2010; Houle et al.,
2001). As such, one might speculate that the potential beneﬁts
of dietary n−3 PUFA on cardiac autonomic regulation could be
more obvious in individuals withmore severe cardiac impairment.
A more severe impairment in autonomic regulation, particularly
during physiological challenges, is consistently noted in VF+ as
compared to VF− animals, yet n−3 PUFA treatment yielded sim-
ilar changes in both groups in the present study. Thus, n−3 PUFA
did not elicit a larger response in the animals with the greatest
autonomic impairment. As the effects of n−3 PUFA treatment
were nearly identical in both VF+ and VF− dogs, these data
suggest that perhaps, rather than altering cardiac autonomic reg-
ulation, these lipids exert their actions via changes in the intrinsic
pacemaker rate. Indeed recent in vitro (Verkerk et al., 2009) and
in vivo (Billman and Harris, 2011) studies demonstrate that n−3
PUFA can reduce intrinsic pacemaker ratemost likely via action on
the pacemaker current (I f). Further investigation will be required
to determine the physiological mechanisms responsible for n−3
PUFA mediated changes in HR.
Third, selecting human-equivalent doses of n−3 PUFA for ani-
mal studies is challenging. The average n−3 PUFA dose (adjusted
for body surface area) was equivalent to about 5 g/day (VF−,
5.34± 0.12 and VF+, 5.17± 0.13 g/day) in human subjects. As
such, this dose is higher than the 1-g/day dose that has been
used in most interventional studies (e.g., Marchioli et al., 2002).
However, it is very close to the dose of prescription n−3 PUFA
(4 g/day, Lovaza®, GlaxoSmithKline) used to treat hypertriglyc-
eridemia (Von Schacky, 2006) and doses up to 8 g/day n−3 PUFA
have been used to evaluate the effect of n−3 PUFA on HRV in
human subjects (Peoples et al., 2008). Furthermore, the doses used
in the present study yielded RBC membrane EPA+DHA levels
that were associatedwith a signiﬁcant reduction in the risk for sud-
den death in epidemiological studies (Siscovick et al., 1995; Albert
et al., 2002). Speciﬁcally, Albert et al. (2002) found that a mean
RBC concentration of 6.9% was associated with a 90% reduction
in the risk for sudden death, a value that compares favorably to
that obtained in the present study (meanRBCconcentration,VF−,
5.5± 0.3% and VF+, 5.4± 0.5%, range 2.3–10.7%).
Finally, although dog and man exhibit a similar cardiac auto-
nomic regulation (Scher et al., 1972), species differences could also
contribute to response differences. One must always use caution
when extrapolating results between species.
CONCLUSION
In the present study, dietary n−3 PUFA (DHA+ EPA ethyl esters,
1–4 g/day for 3months) elicited similar reductions in baseline HR
that were accompanied by similar increases in HRV in dogs that
were susceptible or resistant to VF. However, and in contrast to
endurance exercise training (Billman and Kukielka, 2006, 2007),
n−3 PUFA treatment did not alter the robust autonomic response
(identical increases in HR and decreases in HRV before and after
treatment) induced by either exercise or, more importantly, by
myocardial ischemia in either group of dogs. As both dogs that
were either resistant or susceptible to malignant tachyarrhyth-
mias exhibited similar changes in baseline HR and HRV and in
the response to physiological challenges, it seems unlikely that
changes in HR and HRV are solely responsible for the putative
cardiovascular beneﬁts of these lipids.
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